Unknown

Dataset Information

0

Thrombophilic risk factors for retinal vein occlusion.


ABSTRACT: The aim is to study risk factors for retinal vein occlusion (RVO), such as thrombophilic and cardiovascular risk factors (CRF). A retrospective consecutive case series of 60 patients with RVO was made, tested for CRF, hyperhomocysteinemia, lupic anticoagulant, antiphospholipid antibody and 5 gene variants: factor V (FV) Leiden (G1691A), factor II (PT G20210A), 5,1-methylenetetra-hydrofolate reductase (MTHFR; 677?C?>?T and 1298?A?>?C), plasminogen activator inhibitor 1 (PAI-1; 4?G/5?G). More than 1 CRF were present in 36 patients (60%), which had a significantly higher mean age at diagnosis (66.7?±?12.9 versus 59.5?±?13.7 with ?1 CRF, [t(57)?=?-2.05, p?=?0.045, d?=?0.54). Patients with thermolabile MTHFR forms with decreased enzyme activity (T677T or C677T/A1298C) had a significant lower mean age [57.6?±?15.1; t (58)?=?3.32; p?=?0.002; d?=?0.846] than patients with normal MTHFR enzyme activity (68.5?±?10.2). Regarding CRF and thermolabile forms of MTHFR, the mean age at diagnosis could be significantly predicted [F(2,56)?=?7.18; p?=?0.002] by the equation: 64.8 - 10.3?×?(thermolabile MTHFR) - 5.31?×?(???1CRF). Screening of MTHFR polymorphisms may be useful in younger RVO patients, particularly when multiple CRF are absent.

SUBMITTER: Vieira MJ 

PROVIDER: S-EPMC6908668 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Thrombophilic risk factors for retinal vein occlusion.

Vieira Maria J MJ   Campos António A   do Carmo Anália A   Arruda Henrique H   Martins Joana J   Sousa João P JP  

Scientific reports 20191212 1


The aim is to study risk factors for retinal vein occlusion (RVO), such as thrombophilic and cardiovascular risk factors (CRF). A retrospective consecutive case series of 60 patients with RVO was made, tested for CRF, hyperhomocysteinemia, lupic anticoagulant, antiphospholipid antibody and 5 gene variants: factor V (FV) Leiden (G1691A), factor II (PT G20210A), 5,1-methylenetetra-hydrofolate reductase (MTHFR; 677 C > T and 1298 A > C), plasminogen activator inhibitor 1 (PAI-1; 4 G/5 G). More than  ...[more]

Similar Datasets

| S-EPMC3563864 | biostudies-literature
| S-EPMC6600806 | biostudies-literature
| S-EPMC6687171 | biostudies-literature
| S-EPMC6459468 | biostudies-literature
2015-07-30 | PXD001800 | Pride
| S-EPMC4177949 | biostudies-literature
| S-EPMC6513508 | biostudies-literature
| S-EPMC5648234 | biostudies-literature
| S-EPMC4849670 | biostudies-literature
| S-EPMC8264517 | biostudies-literature